RU2006101859A - Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина - Google Patents
Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина Download PDFInfo
- Publication number
- RU2006101859A RU2006101859A RU2006101859/04A RU2006101859A RU2006101859A RU 2006101859 A RU2006101859 A RU 2006101859A RU 2006101859/04 A RU2006101859/04 A RU 2006101859/04A RU 2006101859 A RU2006101859 A RU 2006101859A RU 2006101859 A RU2006101859 A RU 2006101859A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound
- oxazol
- methylpropyl
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (8)
1. Соединение формулы (I)
в котором R1 представляет собой 2-инданил, R2 представляет собой 1-метилпропил, R3 представляет собой 2-метил-1,3-оксазол-4-ил и R4 и R5 вместе с атомом азота, к которому они присоединены, представляют собой морфолино.
2. (3R,6R)-3-(2,3-дигидро-1Н-инден-2-ил)-1-[(1R)-1-(2-метил-1,3-оксазол-4-ил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1S)-1-метилпропил]-2,5-пиперазиндион.
3. (3R,6R)-3-(2,3-дигидро-1Н-инден-2-ил)-1-[(1R)-1-(2-метил-1,3-оксазол-4-ил)-2-(4-морфолинил)-2-оксоэтил]-6-[(1R)-1-метилпропил]-2,5-пиперазиндион.
4. Фармацевтическая композиция, включающая соединение формулы (I), по п.1 вместе с одним или несколькими фармацевтически приемлемыми носителями.
5. Соединение формулы (I) по п.1 для использования в терапии.
6. Применение соединения формулы (I) по п.1 для производства медицинского препарата, направленного против действия окситоцина на окситоциновый рецептор.
7. Способ лечения или предотвращения заболеваний или состояний, связанных с действием окситоцина, который включает введение млекопитающему, нуждающемуся в этом, эффективного количества соединения формулы (I).
8. Способ А получения соединений формулы (I), который включает
(а) взаимодействие соединения формулы (II)
в котором R1, R2 и R3 имеют значения, определенные в п.1, или его смешанного ангидрида с амином NHR4R5, в котором R4 и R5 имеют значения, определенные в формуле (I), в стандартных условиях получения амидов из карбоновой кислоты или ее смешанного ангидрида и амина, или
(b) введение в реакцию соединения формулы (III)
в котором R1, R2 и R3 имеют значения, определенные в п.1, и R6 представляет собой 2-гидроксифенил с карбонилдиимидазолом или тиокарбонилдиимидазолом в подходящем растворителе и последующую реакцию полученного таким образом продукта с амином NHR4R5, в котором R4 и R5 имеют значения, определенные в формуле (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314738.6 | 2003-06-24 | ||
| GB0314738A GB0314738D0 (en) | 2003-06-24 | 2003-06-24 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006101859A true RU2006101859A (ru) | 2006-06-10 |
| RU2343152C2 RU2343152C2 (ru) | 2009-01-10 |
Family
ID=27637257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006101859A RU2343152C2 (ru) | 2003-06-24 | 2004-06-22 | Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8071594B2 (ru) |
| EP (1) | EP1641787B1 (ru) |
| JP (1) | JP5128126B2 (ru) |
| KR (1) | KR101131378B1 (ru) |
| CN (2) | CN100404532C (ru) |
| AR (1) | AR044869A1 (ru) |
| AT (1) | ATE361295T1 (ru) |
| AU (1) | AU2004251868B2 (ru) |
| BR (1) | BRPI0411729A (ru) |
| CA (1) | CA2530310C (ru) |
| CY (1) | CY1107703T1 (ru) |
| DE (1) | DE602004006268T2 (ru) |
| DK (1) | DK1641787T3 (ru) |
| EG (1) | EG24929A (ru) |
| ES (1) | ES2285474T3 (ru) |
| GB (1) | GB0314738D0 (ru) |
| HK (1) | HK1088910A1 (ru) |
| HR (1) | HRP20070286T3 (ru) |
| IL (1) | IL172529A (ru) |
| IS (1) | IS2463B (ru) |
| MA (1) | MA27887A1 (ru) |
| MX (1) | MXPA05014068A (ru) |
| MY (1) | MY140653A (ru) |
| NO (1) | NO332677B1 (ru) |
| NZ (1) | NZ544006A (ru) |
| PL (1) | PL1641787T3 (ru) |
| PT (1) | PT1641787E (ru) |
| RU (1) | RU2343152C2 (ru) |
| TW (1) | TWI340745B (ru) |
| WO (1) | WO2005000840A1 (ru) |
| ZA (1) | ZA200509890B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0314738D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414100D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US8716286B2 (en) | 2009-10-30 | 2014-05-06 | Glaxo Group Limited | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione |
| CN106999497A (zh) | 2014-06-16 | 2017-08-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗早产的瑞托西班 |
| AU2017205254B2 (en) | 2016-01-04 | 2021-05-20 | Xoma (Us) Lcc | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| MA52548A (fr) | 2016-07-21 | 2021-05-26 | ObsEva SA | Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches |
| CN106674031A (zh) * | 2016-11-18 | 2017-05-17 | 浙江工业大学 | R‑2‑二氢茚氨酸的制备方法 |
| KR20220075340A (ko) | 2019-09-03 | 2022-06-08 | 옵스에파 에스에이 | 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투여 요법 |
| CN115380122A (zh) | 2020-02-10 | 2022-11-22 | 奥布赛瓦股份公司 | 用于催产素受体拮抗剂疗法的生物标志物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596819A (en) * | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
| US5091387A (en) * | 1990-03-02 | 1992-02-25 | Merck & Co., Inc. | Spirocyclic oxytocin antagonists |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5817751A (en) * | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
| US5968938A (en) * | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
| GB2326639A (en) | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
| AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
| SK10642000A3 (sk) | 1998-01-29 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Spôsob prípravy n-[(alifatickej alebo aromatickej)karbonyl)]-2- aminoacetamidovej zlúčeniny a cyklizovanej formy tejto zlúčeniny |
| AU3087099A (en) * | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
| GB2372740A (en) | 2001-01-17 | 2002-09-04 | Xenova Ltd | Diketopiperazines |
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| US20030229001A1 (en) | 2002-01-31 | 2003-12-11 | Pfizer Inc. | Treatment of male sexual dysfunction |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0314733D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| GB0414092D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414100D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| EP2760473A1 (en) | 2011-09-27 | 2014-08-06 | Biomed Valley Discoveries, Inc. | Compositions and methods of treating gliomas |
-
2003
- 2003-06-24 GB GB0314738A patent/GB0314738D0/en not_active Ceased
-
2004
- 2004-06-22 AU AU2004251868A patent/AU2004251868B2/en not_active Ceased
- 2004-06-22 DE DE200460006268 patent/DE602004006268T2/de active Active
- 2004-06-22 DK DK04740230T patent/DK1641787T3/da active
- 2004-06-22 KR KR1020057024715A patent/KR101131378B1/ko active IP Right Grant
- 2004-06-22 ES ES04740230T patent/ES2285474T3/es active Active
- 2004-06-22 MX MXPA05014068A patent/MXPA05014068A/es active IP Right Grant
- 2004-06-22 PT PT04740230T patent/PT1641787E/pt unknown
- 2004-06-22 AT AT04740230T patent/ATE361295T1/de active
- 2004-06-22 CN CNB2004800178348A patent/CN100404532C/zh not_active Expired - Fee Related
- 2004-06-22 US US10/561,498 patent/US8071594B2/en not_active Expired - Fee Related
- 2004-06-22 PL PL04740230T patent/PL1641787T3/pl unknown
- 2004-06-22 NZ NZ544006A patent/NZ544006A/en unknown
- 2004-06-22 MY MYPI20042430 patent/MY140653A/en unknown
- 2004-06-22 JP JP2006516041A patent/JP5128126B2/ja not_active Expired - Fee Related
- 2004-06-22 AR ARP040102182 patent/AR044869A1/es not_active Application Discontinuation
- 2004-06-22 RU RU2006101859A patent/RU2343152C2/ru not_active IP Right Cessation
- 2004-06-22 EP EP04740230A patent/EP1641787B1/en active Active
- 2004-06-22 BR BRPI0411729 patent/BRPI0411729A/pt not_active Application Discontinuation
- 2004-06-22 CN CNA2008101088194A patent/CN101597282A/zh active Pending
- 2004-06-22 CA CA 2530310 patent/CA2530310C/en not_active Expired - Fee Related
- 2004-06-22 WO PCT/EP2004/006814 patent/WO2005000840A1/en active IP Right Grant
- 2004-06-23 TW TW093118010A patent/TWI340745B/zh not_active IP Right Cessation
-
2005
- 2005-12-06 ZA ZA200509890A patent/ZA200509890B/en unknown
- 2005-12-12 IL IL172529A patent/IL172529A/en active IP Right Grant
- 2005-12-21 MA MA28677A patent/MA27887A1/fr unknown
- 2005-12-21 EG EGNA2005000854 patent/EG24929A/xx active
-
2006
- 2006-01-20 IS IS8248A patent/IS2463B/is unknown
- 2006-01-24 NO NO20060383A patent/NO332677B1/no not_active IP Right Cessation
- 2006-08-22 HK HK06109351A patent/HK1088910A1/xx not_active IP Right Cessation
-
2007
- 2007-06-29 HR HR20070286T patent/HRP20070286T3/xx unknown
- 2007-07-24 CY CY071100990T patent/CY1107703T1/el unknown
-
2011
- 2011-09-13 US US13/231,211 patent/US8357685B2/en not_active Expired - Fee Related
-
2012
- 2012-12-14 US US13/715,433 patent/US20130102783A1/en not_active Abandoned
-
2013
- 2013-11-05 US US14/072,376 patent/US8937179B2/en not_active Expired - Fee Related
-
2014
- 2014-12-15 US US14/570,812 patent/US20150105387A1/en not_active Abandoned
-
2015
- 2015-11-20 US US14/946,920 patent/US9452169B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126344T2 (de) | Isoindolimid-verbindungen, zusammensetzungen und verwendungen | |
| DE60034139T2 (de) | Pharmazeutisch-aktive isoindolin-derivate | |
| DE60126324T2 (de) | Pharmazeutisch wirksame isoindolinderivate | |
| US5420155A (en) | Tetramic acid derivatives | |
| DE60127595T2 (de) | Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen | |
| DE69433744T2 (de) | 3-amino-5-carboxy-substituierte piperidine und 3-amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten | |
| DE69629670T2 (de) | Lactam-enthaltende hydroxamsäure-derivate, deren herstellung und deren verwendung als inhibitoren von matrix-metalloproteasen | |
| RU2007102272A (ru) | Замещенные дикетопиперазины в качестве антагонистов | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| RU2006101859A (ru) | Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина | |
| CH616674A5 (ru) | ||
| RU2007102274A (ru) | Пиперазиндионы как антагонисты рецептора окситоцина | |
| KR890000483A (ko) | 피라졸로 피리딘 화합물 및 그들의 제조방법 | |
| RU99109576A (ru) | Амины аминотиофенкарбоновой кислоты и их применение | |
| RU2004137278A (ru) | Новые трициклические спиропиперидины или спиропирролидины | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| KR20230048373A (ko) | 저분자량 단백질 분해제 및 이의 응용 | |
| US5426106A (en) | Pyrrolo-pyridazinone derivatives | |
| RU95106675A (ru) | 3-индолилпиперидины, способ их получения, фармацевтическая композиция и способ ее получения | |
| JP2020515516A5 (ru) | ||
| DE60008218T2 (de) | Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren | |
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| RU97117590A (ru) | Пирролидинильные производные гидроксамовой кислоты и способ их получения | |
| JP2008056700A (ja) | 精神障害及び眼障害の治療用ｓ−メチル−ジヒドロ−ジプラシドン | |
| JP2006512321A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180623 |